Vol. IV · Genetics, Breeders & Chemistry

How modern cannabis was bred —
and the people who shaped it.

Nearly every strain prescribed in a UK clinic today can be traced back to fewer than a dozen heritage lines and a small handful of breeders who, between the 1970s and the 1990s, crossed Afghan, Thai, Mexican and Colombian landraces into the modern hybrid catalogue. This page traces that lineage, profiles the breeders behind it, and compiles the terpene and cannabinoid references that underpin contemporary medical prescribing.

I · The breeding history

Six decades, from hashish trails to the GMP catalogue.

  1. Pre-1960s

    Landrace economies

    Centuries of regional cultivation in the Hindu Kush, Rif, Sinai, Mexico, Colombia, Thailand and southern Africa produced stable, locally-adapted populations. Hashish economies in Afghanistan and Morocco selected hard for resin yield; equatorial regions selected for long-flowering, high-THC sativas.

  2. 1965 – 1975

    The hippie trail & seed migration

    Western travellers carried seeds out of Afghanistan, Nepal, Thailand and Mexico back to California, the Pacific Northwest and the Netherlands. The first deliberate Indica × Sativa crosses were made by hobbyists in Santa Cruz, Humboldt and Oregon.

  3. 1976 – 1982

    Skunk #1 & the modern hybrid

    Sam the Skunkman and the Sacred Seeds collective stabilised Skunk #1 (Afghani × Acapulco Gold × Colombian Gold) — the first true polyhybrid bred for indoor production. It would become the genetic backbone of almost every modern commercial strain.

  4. 1983 – 1989

    The Dutch transfer

    Following the 1982 US Sinsemilla Tips bust, Sam the Skunkman moved to Amsterdam with the Skunk #1 line. Neville Schoenmakers founded The Seed Bank (later Sensi Seeds) and began distributing North American genetics — Northern Lights, Haze, Skunk — across Europe.

  5. 1990 – 1999

    Cup-era diversification

    The High Times Cannabis Cup (est. 1988) accelerated competitive breeding. DJ Short released Blueberry; Soma released NYC Diesel and Lavender; Arjan Roskam founded Green House Seeds; Jorge Cervantes' grow guides industrialised indoor cultivation worldwide.

  6. 2000 – 2009

    OG Kush & the West Coast renaissance

    OG Kush (likely Chemdawg × Hindu Kush × Lemon Thai) emerged in California, alongside Sour Diesel, Girl Scout Cookies' precursors, and the rise of clone-only elite cuts traded between dispensaries. Subcool's TGA Genetics popularised stable, seed-form hybrids of these elites.

  7. 2010 – 2017

    Medical legitimisation

    Bedrocan (NL) became the first EU producer to supply pharmacy-grade, standardised flower under GMP. CBD-rich strains like Charlotte's Web, Cannatonic and ACDC were stabilised. Israeli and Canadian research groups began publishing on the entourage effect.

  8. 2018 – present

    UK prescribing & the GMP catalogue

    Medical cannabis was rescheduled in the UK in November 2018. Producers such as Bedrocan, Aurora, Tilray, Khiron, Cantourage, Adven and Noidecs now supply UK pharmacies with strains whose genetics nearly all descend from the Skunk / Haze / OG Kush / Cookies lineages established by the breeders profiled below.

II · Pioneer breeders

The people whose pheno-hunts you are still smoking.

USA → Netherlands · 1970s – present

David Watson

a.k.a. Sam the Skunkman

Founded · Sacred Seeds (1976), Cultivator's Choice (1985)

Stabilised Skunk #1, the foundational polyhybrid behind most modern strains, and brought elite American genetics to the Netherlands after the 1982 Sinsemilla Tips raid.

Working out of Santa Cruz in the late 1970s, Sam crossed Afghani indica with Acapulco Gold and Colombian Gold to produce Skunk #1 — the first strain bred specifically for indoor production. After fleeing US prosecution, he carried the line to Amsterdam, where it seeded the Dutch industry.

Notable releases

  • Skunk #1
  • Original Haze (preservation)
  • Cultivator's Choice catalogue

Australia → Netherlands · 1980s – 2000s

Neville Schoenmakers

Founded · The Seed Bank of Holland (1984)

The first commercial cannabis seed company. Distributed Northern Lights, Haze, Skunk, Hash Plant and Big Bud across Europe, professionalising the breeder catalogue model.

Neville turned underground genetics into a mail-order industry. The Seed Bank's 1987 catalogue is considered the founding document of European commercial breeding. Sensi Seeds later acquired the brand.

Notable releases

  • Northern Lights #5
  • Neville's Haze
  • Hash Plant

USA · 1980s – present

DJ Short

Founded · DJ Short Genetics

Defined the modern indica fruit-flavour palette through long, patient pheno-hunts of Highland Thai and Oaxacan lines.

Working with Pacific Northwest growers from the early 1980s, DJ Short pursued pheno selection over decades, releasing Blueberry — the first strain to consistently express true blueberry terpene character — in the early 1990s.

Notable releases

  • Blueberry
  • Flo
  • Blue Velvet

USA → Netherlands · 1990s – present

Soma

Founded · Soma Seeds (1996)

Pioneered organic, hand-pollinated breeding in Amsterdam and authored some of the most influential CBD-dominant and high-myrcene strains in modern medical use.

Born Michael Strauss, Soma left the US for Amsterdam in 1993 and quickly became one of the most respected Cannabis Cup competitors. His emphasis on terpene character and organic technique influenced an entire generation of European breeders.

Notable releases

  • NYC Diesel
  • Lavender
  • Somango
  • Soma A+

Netherlands · 1990s – present

Arjan Roskam

Founded · Green House Seeds (1985 coffeeshop, 1995 seed co.)

Industrialised the breeder-celebrity model and won more Cannabis Cups than any other operator. Pioneered the modern landrace-hunting project ('Strain Hunters') that catalogued surviving sativa populations in Malawi, Congo and India.

From his Green House coffeeshop in Amsterdam, Arjan and Franco Loja crossed elite cup-winners with field-collected landraces, releasing some of the highest-THC strains of the 2000s. The Strain Hunters expeditions remain the most documented modern landrace fieldwork.

Notable releases

  • White Widow
  • Super Lemon Haze
  • Super Silver Haze
  • Hawaiian Snow

USA · 2000s – 2020

Subcool

Founded · TGA Genetics / Subcool Seeds (2001)

Stabilised California elite cuts into seed form, making clone-only flavours like Jack the Ripper and Querkle accessible to home and craft growers worldwide.

Subcool (Marc Emery's contemporary, born John Schroyer) emphasised seed-stock stability and authored 'Dank: The Quest for the Very Best Marijuana,' one of the most-read breeding texts of the 2000s.

Notable releases

  • Jack the Ripper
  • Querkle
  • Vortex
  • Chernobyl

Canada · 1990s – 2010s

Reeferman

Founded · Reeferman Seeds (1999)

Preserved and re-released a large catalogue of pre-Skunk North American heritage lines, including Love Potion and Original Northern Lights.

Working from British Columbia, Reeferman focused on heritage preservation at a time when most of the industry was chasing potency, keeping pre-1980s genetics in circulation.

Notable releases

  • Love Potion #1
  • Cripple Creek
  • Original Haze preservation

USA · 2000s – present

Ben Holmes

Founded · Centennial Seeds (2009)

One of the first breeders to apply Mendelian rigour and HPLC chemotyping to cannabis, defining the modern Type II (1:1 THC:CBD) and Type III (CBD-dominant) chemovars used in medical practice.

Based in Colorado, Holmes' chemotype-driven breeding made standardised CBD:THC ratios reproducible at scale and underpins much of today's medical CBD-rich catalogue.

Notable releases

  • Cannatonic line work
  • Type II chemovar stabilisation

Netherlands · 2003 – present

Bedrocan B.V.

Founded · Bedrocan (2003)

The first company to produce GMP-grade, batch-standardised cannabis flower for pharmacy dispensing — the model every UK medical producer now follows.

Operating under contract to the Dutch Office for Medicinal Cannabis (OMC), Bedrocan demonstrated that cannabinoid and terpene profiles could be held within ±5% batch-to-batch, opening the door to medical prescribing across Europe.

Notable releases

  • Bedrocan (22% THC Jack Herer pheno)
  • Bediol
  • Bedrolite
  • Bedica

III · The family tree

Four root lineages feed almost every modern hybrid.

IV · Terpene reference

The aromatic compounds that shape the experience.

Terpenes are volatile aromatic molecules shared with herbs, fruits and conifers. In cannabis they are concentrated in the trichome heads alongside the cannabinoids. The entourage-effect hypothesis (Russo, 2011) proposes that the combination of cannabinoids and terpenes — not THC alone — accounts for strain-specific clinical effects.

Myrcene

BP 167 °C

Aroma · Earthy, musky, ripe mango, clove

Also in · Mango, hops, lemongrass, thyme

Sedating, muscle-relaxant character; the dominant terpene in most indica-leaning UK strains.

Russo (2011) proposed myrcene as a key driver of the 'couch-lock' phenotype; reviewed in Br J Pharmacol 163(7).

Limonene

BP 176 °C

Aroma · Bright citrus peel, lemon, orange

Also in · Citrus rind, juniper, peppermint

Elevating, anxiolytic in animal models; commonly reported as mood-lifting by patients.

Komori et al. (1995) Neuroimmunomodulation 2(3): citrus limonene inhalation reduced depression scores in hospitalised patients.

Caryophyllene (β-)

BP 119 °C

Aroma · Black pepper, warm wood, clove

Also in · Black pepper, cloves, rosemary

The only known dietary cannabinoid agonist — binds CB2 directly. Anti-inflammatory potential.

Gertsch et al. (2008) PNAS 105(26): β-caryophyllene is a selective CB2 agonist with documented anti-inflammatory action.

Pinene (α-)

BP 156 °C

Aroma · Fresh pine needles, rosemary

Also in · Pine, basil, parsley, dill

Bronchodilator and acetylcholinesterase inhibitor — may counter THC-induced short-term memory impairment.

Russo (2011); also Kennedy et al. (2011) on rosemary aroma and cognitive performance.

Linalool

BP 198 °C

Aroma · Lavender, floral, soft spice

Also in · Lavender, coriander, birch

Anxiolytic and mild sedative in rodent and human aromatherapy studies; often present in 'night-time' chemovars.

Linck et al. (2010) Phytomedicine 17: inhaled linalool reduced anxiety-like behaviour in mice.

Terpinolene

BP 186 °C

Aroma · Fresh herbal, apple, cumin

Also in · Nutmeg, tea tree, lilac

Often the marker terpene in 'energetic' Haze-derived sativas; mild antioxidant activity in vitro.

Aoshima et al. (2006) noted sedative behaviour in mice, contradicting popular 'uplifting' claims — evidence remains mixed.

Humulene

BP 106 °C

Aroma · Hops, earthy, slightly bitter

Also in · Hops, sage, ginseng

Anti-inflammatory in murine models; appears in most caryophyllene-dominant chemovars.

Fernandes et al. (2007) Eur J Pharmacol 569(3): humulene reduced inflammation comparably to dexamethasone in mice.

Ocimene

BP 100 °C

Aroma · Sweet, herbal, woody, citrus

Also in · Mint, parsley, basil, orchids

Decongestant; antifungal and antibacterial in vitro studies of basil and orchid extracts.

Less cannabis-specific data; characterisation reviewed in Booth & Bohlmann (2019) Plant Sci 284.

V · Cannabinoid reference

The molecules behind the prescription.

Cannabis produces more than 120 cannabinoids. Only a handful appear in clinically meaningful quantity. UK GMP analyses currently report THC, CBD and (increasingly) CBG, CBN and THCV. The acidic forms (THCA, CBDA) dominate in raw flower and convert to their neutral forms when vaporised or heated.

CannabinoidIntoxicating
THC
Δ9-Tetrahydrocannabinol
Yes
CBD
Cannabidiol
No
CBG
Cannabigerol
No
CBN
Cannabinol
Mild
CBC
Cannabichromene
No
THCV
Tetrahydrocannabivarin
Mild
CBDV
Cannabidivarin
No
THCA
Δ9-Tetrahydrocannabinolic acid
No

THC

Δ9-Tetrahydrocannabinol

Major

The principal intoxicating cannabinoid. Analgesic, antiemetic, appetite-stimulating, muscle-relaxant. Dose-dependent anxiogenic effect above patient tolerance.

Evidence · Whiting et al. (2015) JAMA 313(24): moderate-quality evidence for chronic pain and spasticity; supports current UK specialist prescribing pathways.

CBD

Cannabidiol

Major

Non-intoxicating. Anxiolytic, anticonvulsant, anti-inflammatory. Modulates the subjective effects of THC.

Evidence · Epidyolex (CBD) is licensed in the UK for Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis (NICE TA614, TA615, TA873).

CBG

Cannabigerol

Minor

The 'mother cannabinoid' — biosynthetic precursor to THC, CBD and CBC. Investigated for IBD, glaucoma and antibacterial activity.

Evidence · Borrelli et al. (2013) Biochem Pharmacol 85(9): CBG reduced colitis in murine models. Human trials limited.

CBN

Cannabinol

Minor

Oxidative degradation product of THC; accumulates in aged flower. Widely marketed as sedating, though human sleep data is limited.

Evidence · Karniol et al. (1975) suggested CBN potentiates THC sedation. Most modern claims rest on this 1970s data — current evidence remains thin.

CBC

Cannabichromene

Minor

Non-intoxicating; investigated for anti-inflammatory and neurogenic activity. Often the third-most-abundant cannabinoid in CBD-rich flower.

Evidence · Shinjyo & Di Marzo (2013) Neurochem Int 63(5): CBC promoted adult neural stem progenitor cell viability in vitro.

THCV

Tetrahydrocannabivarin

Variant

Propyl analogue of THC. Appetite-suppressing at low doses; investigated for metabolic syndrome and type II diabetes.

Evidence · Jadoon et al. (2016) Diabetes Care 39(10): THCV improved glycaemic control in a 13-week RCT of type II diabetics.

CBDV

Cannabidivarin

Variant

Propyl analogue of CBD. Investigated for autism-spectrum behaviours and refractory epilepsy.

Evidence · GW Pharma's GWP42006 (CBDV) trials in autism showed mixed results; pre-clinical anticonvulsant data is consistent (Hill et al., 2012 Br J Pharmacol).

THCA

Δ9-Tetrahydrocannabinolic acid

Acidic

The raw, non-decarboxylated form present in fresh flower. Becomes THC on heating (~104 °C). Investigated for anti-inflammatory and neuroprotective activity.

Evidence · Nallathambi et al. (2018) Cannabis Cannabinoid Res 3(1): THCA reduced colon inflammation in vitro and in murine models.

Evidence note

Cannabis pharmacology is an active research area with significant gaps. Many of the receptor and effect claims summarised above rest on pre-clinical or small-cohort evidence. This page is educational and historical — it is not medical advice. Medical cannabis in the UK is a prescription-only medication and must be initiated by a GMC-registered specialist. See NICE NG144.